SSG
GNMX

Summit Securities Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Summit Securities Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25
Closed – – 682
2014
Q1 		$0 Buy
+25
New +$195 ﹤0.01% 635

Other funds holding GNMX

Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Summit Securities Group's GNMX Position: Q2 2014 in Review

Summit Securities Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2014, closing a stake of 25 shares.

Summit Securities Group first reported a position in GNMX in Q1 2014 and held it in 1 quarter. The position peaked at $0 in Q1 2014. 27 funds tracked by Wall St. Rank hold GNMX as of Q2 2014.

  • Summit Securities Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2014 after selling out during the quarter.
  • Summit Securities Group sold 25 Aevi Genomic Medicine Inc shares in Q2 2014.
  • Summit Securities Group first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 1 quarter.
  • Summit Securities Group's Aevi Genomic Medicine Inc position peaked at $0 in Q1 2014.
  • 27 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2014.

Based on Summit Securities Group's 13F filing for Q2 2014, filed 12 Aug 2014.